SOLICITATION NOTICE
B -- DNA Methylation and Gastric Cancer Risk
- Notice Date
- 8/14/2008
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80183-NG
- Archive Date
- 9/13/2008
- Point of Contact
- Ashley L. Virts, , Malinda L Holdcraft,, Phone: (301) 402-4509
- E-Mail Address
-
virtsa@mail.nih.gov, holdcram@exchange.nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB), plans to procure services regarding DNA methylation and gastric cancer risk in a Polish and Chinese Population with the Molecular Epidemiology Laboratory, Department of Occupational and Environmental Health, University of Milan; Via Festa Del Perdono 7, Milan, Italy 20122. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 611310 and the business size standard is 6.5M employees. The purpose of this project is to perform DNA methylation analysis on DNA from peripheral blood lymphocytes from stomach cancer cases and matched control subjects in the Shanghai Women's Health Study and the Polish stomach cancer study. DNA methylation is an epigenetic mechanism that regulates chromosomal stability and gene expression and is linked to both transcriptional silencing and activation. Abnormal DNA methylation patterns have been observed in many types of human tumors, since cells with abnormal DNA methylation acquire an overall gene expression pattern that favors proliferation and differentiation, leading to neoplastic transformation. In young, healthy mammals, CpG island cytosine is almost universally unmethylated, and the methylation of cytosines in these regions is known as hypermethylation. CpG island hypermethylation in the promoter regions of a gene is associated with transcriptional silencing of genes that would normally be expressed, such as tumor suppressor genes. A significant association between gastric cancer risk and polymorphisms has been noted in several genes. Carriers of a variant ALDH2 allele associated with deficiency in elimination of acetaldehyde, an alcohol metabolite, are at an increased risk of gastric cancer if they drink alcohol. Carriers of the TLR4 polymorphism linked with impaired reactivity to bacterial lipopolysaccharide have significantly more severe gastric atrophy and inflammation, and an increased risk of gastric cancer. There is evidence that suggests polymorphisms in the mucin genes may be related to gastric cancer risk. These genes encode the glycosylated glycoproteins that constitute the major components of the mucous protective layer in the stomach. CpG islands are present in a number of genes involved in these pathways, including ALDH2, TLR4, MUC1, MUC5AC, and MUC6, and are therefore potential targets for methylation leading to epigenetic silencing. The purpose of the proposed contract is to examine hypermethylation in these genes is related to gastric cancer risk, and to explore whether the associations are modified by environmental factors, such as alcohol drinking and Helicobacter pylori infection. The contractor shall: 1.Perform bisulfite treatment of DNA from peripheral blood lymphocyte samples from 700 subjects in the Polish stomach cancer study and 500 subjects in the Shanghai Women’s Health Study. 2.Perform PCR amplification and pyrosequencing for methylation analysis in the promoter region of the following genes: -ALDH2, TLR4, MUC1, MUC5, and MUC6 in 700 samples from the Polish stomach cancer study -MUC1, MUC5, and MUC 6 in 500 samples from the Shanghai Women’s Health Study 3.The methylation analysis for the Polish stomach cancer study samples shall be conducted in duplicates. 4.The methylation analysis for the Shanghai Women’s Health Study samples shall be conducted in triplicates. 5.Deliver results for the MUC genes within eight months after receipt of the samples and the ALDH2 and TLR4 results within 11 months after receipt of the samples. 6. Prepare a technical report on the details of the standard operative procedures used in bisulfite treatment, PCR amplification, and DNA methylation analysis. The Period of Performance shall be twelve months from the date of award. The University of Milan, Molecular Epidemiology Laboratory is the only institution worldwide to have pyrosequencing equipment for methylation analysis dedicated exclusively to environmental health-related research. The pyrosequencing technology on bisulfite treated DNA has the sensitivity and accuracy to detect very small changes in DNA methylation, such as those that are of interest in epidemiologic studies. The laboratory implements standardized quality control procedures that take full advantage of the pyrosequencing potential. In particular, the QC procedures permit accurate determination whether bisulfite treatment, a critical step in DNA methylation analysis, resulted in complete cytosine conversion. The Molecular Epidemiology Laboratory has conducted analysis of DNA methylation in relation to gastric cancer risk in the Polish and the Shanghai studies. The conduction of the DNA methylation analyses in the same lab will allow NCI to simplify the control of laboratory operations and guarantee standardized quality control procedures. The University of Milan, Molecular Epidemiology Laboratory is the only source known to the NCI that can perform the analysis outlined in the procurement. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 11:00 a.m. ET on August 29, 2008. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Malinda Holdcraft: holdcram@exchange.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-80183-NG on all correspondence.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=d13f0f340cb840e75a7af09fa5026ac2&tab=core&_cview=1)
- Record
- SN01640789-W 20080816/080814223915-d13f0f340cb840e75a7af09fa5026ac2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |